ArticleScientific reports2026
Double functionalized Sindbis E2 glycoprotein modifies Sindbis tropism favouring infection of α5β1⁺ glioblastoma cells.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Effective cancer therapy hinges on the ability to selectively target malignant cells while sparing healthy tissues. For virotherapy this goal can be achieved by genetic engineering the surface glycoproteins of viruses. This approach, though, often leads to loss of functionality of the engineered proteins, in terms of membrane fusion. Here, we modified the E2 protein of Sindbis virus, preserving the ability of transduction by lentivectors pseudotyped by the Sindbis Env proteins. The modifications introduced allowed to alter the efficiency of transduction of glioblastoma cells expressing integrin α5β1, a driver of resistance to treatments and frequently associated to recurrences. Importantly, the same modifications of E2 also conferred, to a replication-competent Sindbis strain, the ability to kill preferentially α5β1⁺ over α5β1⁻ glioblastoma cells in culture. Finally, the same strain reduced the expansion of α5β1⁺ glioblastoma cancers in the brain of immunodeficient mice when injected in the tail vein.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.